Protiva Biotherapeutics Inc., a development stage biotechnology company focused on the advancement of pharmaceutical products to fight serious human diseases such as cardiovascular disease and cancer, announced today the completion of a convertible debenture financing with commitments of CAD$5.6 million. This third round of financing brings Protiva’s cumulative venture capital financing to CAD$26 million.
